If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Fisher and Sons Regulatory News (FSJ)

Share Price Information for James Fisher and Sons (FSJ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 300.00
Bid: 297.00
Ask: 304.00
Change: 3.00 (1.01%)
Spread: 7.00 (2.357%)
Open: 291.00
High: 305.00
Low: 291.00
Prev. Close: 297.00
FSJ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sale of JFN, Trading Update and Notice of Results

6 Mar 2023 07:00

RNS Number : 9282R
Fisher (James) & Sons plc
06 March 2023
 

This announcement contains inside information

6 March 2023

James Fisher and Sons plc

Sale of JFN, Trading Update and Notice of Results Announcement

 

James Fisher and Sons plc (FSJ.L) ('James Fisher', 'the Group'), the leading provider of marine services, announces that it has sold the entire issued share capital of James Fisher Nuclear Holdings Limited and related properties ("JFN", "the business"), to Myneration Limited, a wholly-owned investment vehicle of Rcapital Partners LLP ("Rcapital").

 

The sale forms part of the Board's ongoing commitment to rationalise and focus the Group's portfolio. Existing management and staff will remain with the business as it transitions into new ownership and Rcapital will provide JFN with a £3m secured revolving credit facility to fund the growth of the business going forward.

 

The Group has historically given a number of parent company guarantees to support the obligations of JFN. These guarantees will remain with James Fisher following completion of the transaction although certain limited counter-indemnities have been put in place. The Group has also received certain limited undertakings and information rights in respect of the principal parent company guarantee remaining in place following completion.

 

Following completion, an unsecured loan of £1.2m which has been made available by the Group to JFN will remain outstanding. It is anticipated that the amount outstanding under that loan will be repaid by JFN shortly after completion. In addition, the Group will make a secured interest-bearing term loan facility of up to £3.5m available to JFN. The Group has also entered into an inter-creditor agreement which sets out the priority of the facilities made available to JFN by Rcapital and the Group.

 

JFN is a supplier of specialist engineering, manufacturing and technical services to the UK's nuclear decommissioning industry. The results of JFN have historically been reported within the Specialist Technical division. The results of JFN will be shown as a Discontinued Operation in the Group's 2022 financial statements. In 2021, the business generated third party revenue of £51.7m and a loss before tax of £0.1m. At 30 June 2022 the unaudited gross assets of the business were approximately £36.4m and its net assets were approximately £17.5m, of which Goodwill represented £8.1m. The Group will sell its interest in James Fisher Nuclear Holdings Limited and certain group companies will sell their interests in the related properties for a nominal consideration of £3. As a result of the transaction the Group will impair the value of goodwill and tangible fixed assets associated with the business in its results for the year ended 31 December 2022.

 

Commenting on the sale, Chief Executive Officer, Jean Vernet, said:

"The sale of JFN is a further step in the implementation of our strategy to rationalise and focus the portfolio and, taken together, the business and asset disposals made over the last three months are important steps in streamlining the Group's operations and strengthening the balance sheet. JFN has some valuable and unique capabilities and requires the right investment to exploit the market opportunities in front of it. In Rcapital we are pleased to have found the right owner for the next chapter in this business's development. We wish the business and its employees every future success."

 

Josie Richardson, Investment Director at Rcapital, added:

"JFN plays a crucial role in the UK's nuclear decommissioning industry and, hence, the delivery of the Government's strategic energy plan. Its management team, market-leading technical services and unique UK-based experience in specialist fields put it in a strong position. We are pleased to have the opportunity to support the business as it enters a new phase of growth and development."

 

Trading update for the year ended 31 December 2022

The Group made good strategic and financial progress during 2022, disposing of three businesses, agreeing the sale of the Swordfish dive support vessel and generating good revenue and underlying operating profit growth across the Marine Support, Offshore Oil and Tankships divisions. The Specialist Technical division experienced a disappointing year, with JFD at a trough in its long-term projects cycle and JFN, which will be reported as a Discontinued Operation, reporting an operating loss following ongoing project challenges.

 

For the year ended 31 December 2022, the Group is expecting to report revenue from continuing operations of c.£475m (2021: £442.4m). Underlying operating profit from continuing operations is anticipated to be in line with 2021.

 

The three business sales completed in December 2022 generated gross proceeds of c.£18.4m. Net bank borrowings at 31 December 2022 were c.£135m, with the Group expecting to remain within its banking covenants. The sale of the Swordfish Dive Support Vessel, which was announced in December 2022, completed in January 2023, with cash proceeds of c.£20m now received. The Group has commenced discussions with its lending group regarding existing borrowing facilities, which have maturity dates ranging from October 2023 to September 2024.

Notice of Results Announcement

The Group's full year results will be published on 28 March 2023, two weeks later than had originally been planned, reflecting the significantly higher-than-normal levels of recent corporate activity and consequential impact on audit timetable.

 

 

 

For further information:

James Fisher and Sons plc

Jean Vernet

Duncan Kennedy

Chief Executive Officer

Chief Financial Officer

020 7614 9500

FTI Consulting

Richard Mountain

Susanne Yule

0203 727 1340

 

 

The person responsible for making this announcement on behalf of the Company is Jean-François Bauer, Group General Counsel.

 

LEI: 213800J975E5OYR6S216

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSIEEIEDSEFD
Date   Source Headline
22nd Mar 20224:35 pmRNSHolding(s) in Company
10th Mar 20227:00 amRNSFull year results for the year ended 31 Dec 21
24th Jan 202210:54 amRNSDirector Declaration
29th Dec 20219:55 amRNSMozambique update
17th Dec 20217:00 amRNSAppointment of non-executive director
15th Dec 20215:36 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20215:22 pmRNSHolding(s) in Company
18th Nov 202110:25 amRNSHolding(s) in Company
2nd Nov 20217:00 amRNSSale of James Fisher Testing Services for £5.7m
1st Nov 20215:23 pmRNSDirector/PDMR Shareholding
25th Oct 20217:00 amRNSTrading update
22nd Oct 20218:00 amRNSAppointment of non-executive director
15th Sep 20211:26 pmRNSDirector/PDMR Shareholding
7th Sep 20217:00 amRNSHalf year results for the 6 months ended 30 Jun 21
1st Jul 20217:00 amRNSSale of Paladin for US$17.3m
29th Jun 20217:00 amRNSCapital Markets Event & Pre Close Trading Update
15th Jun 20213:51 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Jun 20214:16 pmRNSDirector/PDMR Shareholding
30th Apr 202111:59 amRNSDirector Declaration
29th Apr 20212:01 pmRNSResult of Annual General Meeting
29th Apr 20217:00 amRNSAGM Trading Statement
20th Apr 20217:00 amRNSAppointment of Chief Financial Officer
13th Apr 202111:32 amRNSWithdrawal of Annual General Meeting Resolution
9th Apr 202110:18 amRNSDirector/PDMR Shareholding
8th Apr 20213:58 pmRNSDirector/PDMR Shareholding
6th Apr 20213:48 pmRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSTotal Voting Rights and Share Capital
29th Mar 20217:00 amRNSDirectorate Change
23rd Mar 202112:58 pmRNSAnnual Report and Notice of AGM posted
19th Mar 20211:17 pmRNSHolding(s) in Company
11th Mar 20217:00 amRNSResults for the year ended 31 December 2020
25th Feb 202110:42 amRNSNotification of FY Results Date
25th Jan 20217:00 amRNSAngus Cockburn appointed as Chairman
7th Jan 20217:00 amRNSPost close trading update
18th Dec 20204:41 pmRNSSecond Price Monitoring Extn
18th Dec 20204:35 pmRNSPrice Monitoring Extension
15th Dec 202011:18 amRNSBLOCK LISTING SIX MONTHLY RETURN
11th Nov 20207:00 amRNSDirector/PDMR Shareholding
9th Nov 20205:25 pmRNSTotal Voting Rights
6th Nov 20207:00 amRNSTrading Update
2nd Nov 20207:00 amRNSTotal Voting Rights
23rd Oct 20209:48 amRNSDirector/PDMR Shareholding
6th Oct 20203:58 pmRNSDirector/PDMR Shareholding
2nd Oct 20207:00 amRNSRoyal Navy contract award
21st Sep 20204:00 pmRNSDirector/PDMR Shareholding
25th Aug 20207:00 amRNSHalf-year results
24th Jul 202012:00 pmRNSDirector/PDMR Shareholding
7th Jul 20207:00 amRNSHalf year post close trading update
24th Jun 202012:02 pmRNSPrice Monitoring Extension
15th Jun 20207:00 amRNSBLOCK LISTING SIX MONTHLY RETURN

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.